Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud | Hematology | Research Excellence Award

Assistant professor | A’ Sharqiyah University | Oman

Assist. Prof. Dr. Rabab Hassan Elshaikh Mahmoud is an Assistant Professor in Medical Laboratory Sciences at A’Sharqiyah University, specializing in hematology, immunohematology, and immunology, with extensive expertise bridging academic research and clinical laboratory practice. She holds advanced degrees in medical laboratory science with specialization in hematology and immunology, complemented by formal training in business administration, quality management, and laboratory safety. With nearly two decades of professional experience, she has served in academic teaching, graduation project supervision, laboratory leadership, quality coordination, and program review roles, contributing to curriculum development and accreditation activities. Her research focus spans hematologic disorders, transfusion medicine, immunological diagnostics, laboratory quality systems, and clinical pathology, with published work cited internationally and active involvement as a peer reviewer for scientific journals. Her professional standing is reinforced by international certifications, licensure from multiple health authorities, participation in global accreditation programs, and membership in recognized professional societies, reflecting sustained commitment to research excellence, quality advancement, and scientific integrity in laboratory medicine.

Citation Metrics (Google Scholar)

247
200
150
100
50
0

247

6

4

Citations

h-index

i10-index


Top 5 Featured Publications

 

Yi-Shan Liu | Dermatology | Best Researcher Award

Assoc. Prof. Dr. Yi-Shan Liu | Dermatology | Best Researcher Award

Chairman | I-Shou University | Taiwan

Assoc. Prof. Dr. Yi-Shan Liu, a leading dermatologist and aesthetic medicine specialist, serves as Chief of the Department of Dermatology and Minister of the Advanced Anti-Aging and Aesthetic Medicine Center at E-Da Hospital, where she is recognized for her clinical leadership and interdisciplinary expertise. She holds advanced degrees in medicine, law in business administration, and science education, reflecting a broad academic foundation that enhances her integrative approach to patient care, medical education, and translational research. Her professional experience spans progressive roles across major medical centers, where she has led dermatology services, contributed to aesthetic medicine initiatives, and guided multidisciplinary teams in delivering high-standard clinical practices. Her research focuses on dermatology, aesthetics, anti-aging science, and applied corneotherapy, with contributions that extend to scholarly publications, collaborative investigations, and international academic engagement. She has earned appointments as an associate professor across multiple academic programs and is an active member of numerous professional societies in dermatology and related fields, reflecting her recognized standing in the global medical community. Her professional certifications in medicine, dermatology, and hyperbaric and undersea medicine further attest to her clinical competence and commitment to continuous advancement. Dr. Liu’s combination of scholarly accomplishment, leadership experience, research productivity, and professional recognition positions her as an exemplary candidate for distinguished award nomination.

Profiles: ORCID

Featured Publications

1. Li, T. S., Wu, M. S., Sun, C. K., & Liu, Y. S. (2025). A novel banana method for surgical treatment of distal phalangeal glomus tumor. Asian Journal of Surgery, 48(11), 7228–7229.

2. Liu, Y. S., Lai, M. C., Hong, T. Y., & Liu, I. M. (2025). γ-Oryzanol: A nutrient-rich ingredient for promoting wound healing. Heliyon, 11(4), e42551.

3. Liu, Y.-S., Lai, M.-C., Tzeng, Y.-C., & Liu, I.-M. (2025). Polyphenolic hispolon derived from medicinal mushrooms of the Inonotus and Phellinus genera promotes wound healing in hyperglycemia-induced impairments. Nutrients, 17(2), 266.

4. Liu, Y.-S., Lai, M.-C., Hong, T.-Y., & Liu, I.-M. (2024). Exploring the wound healing potential of hispidin. Nutrients, 16(18), 3161.

5. Siregar, P., Liu, Y.-S., Casuga, F. P., Huang, C.-Y., Chen, K. H.-C., Huang, J.-C., Hung, C.-H., Lin, Y.-K., Hsiao, C.-D., & Lin, H.-Y. (2024). Optimization of laser-based method to conduct skin ablation in zebrafish and development of deep learning-based method for skin wound-size measurement. Inventions, 9(2), 25. (Co-first author)

Dr. Yi-Shan Liu’s work advances scientific understanding and clinical practice in dermatology, aesthetic medicine, and wound healing through integrative research and evidence-based innovation. Her contributions support improved patient outcomes, foster translational solutions for regenerative and anti-aging therapies, and strengthen global collaboration in emerging biomedical technologies.

Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Assoc. Prof. Dr. Feyera Gemeda | Infectious Diseases | Outstanding Scientist Award

Associate Professor | Dima Jimma university | Ethiopia

Assoc. Prof. Dr. Feyera Gemeda Dima is a distinguished researcher and academic with extensive experience in Infectious Diseases, Medical Mycology, and Medicine. He has demonstrated excellence in teaching, research, and mentorship at both national and international levels, fostering the development of students and early-career researchers. His work emphasizes innovation in scientific research, editorial contributions, and leadership in grant assessment and curriculum development. He has contributed significantly to global collaborations and serves as a Chief Scientist and Global Assessor, reflecting his commitment to advancing scientific knowledge. His research focuses on improving understanding and management of infectious diseases, with the potential to influence public health strategies. Prof. Gemeda’s dedication to integrating innovative approaches and interdisciplinary perspectives underscores his capacity for impactful contributions in the field.

Profile:  Google Scholar

Featured Publications

1. T. Gizaw and F. G. Dima, “Assessment of problems and constraints associated with artificial insemination service in the two selected districts of Arsi zone,” Journal of Harmonized Research in Medical and Health Sciences, vol. 3, no. 1, pp. 14–37, 2016.

2. A. Edao, F. G. Dima, and F. B. Deressa, “Prevalence of bovine cysticercosis and status of human taeniasis in and around Asella town, Tiyoworeda, south east Ethiopia,” Glob J Med Res, vol. 16, pp. 18–26, 2016.

3. F. Gemeda, “Prevalence of bovine Trypanosomosis in and around Nekemte areas, east Wollega zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 05, p. 1, 2015.

4. D. T. Legesse and F. Gemeda, “Comparison of two parasitological tests and post mortem examination to detect prevalence of bovine fasciolosis at Ambo Town Municipal Abattoir, West Shewa Zone, Ethiopia,” Open Access Library Journal, vol. 2, no. 8, pp. 1–5, 2015.

5. F. G. Dima and T. Fikedu, “Review on infectious bovine keratoconjunctivitis,” J Bacteriol Infect Dis, vol. 4, no. 4, pp. 1–6, 2021.

Dr. Gemeda’s work advances the understanding and control of infectious diseases, providing evidence-driven insights that strengthen public health systems and guide global disease management strategies.

Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Dr. Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Research Associate | Iran University of Medical Sciences | Iran

Dr. Milad Shirvaliloo is an accomplished physician–researcher specializing in epigenetics with a focus on cancer and pulmonary medicine. Holding a Doctor of Medicine and a Master of Business Administration in Health Sciences, he combines clinical expertise with research innovation to advance precision medicine. As a Postgraduate Researcher at the Finetech in Medicine Research Center, he leads studies on nanoparticle-based therapeutic interventions and their effects on histone acetylation in cancer. Dr. Shirvaliloo has authored more than forty peer-reviewed publications and a book chapter, contributing extensively to understanding molecular and epigenetic mechanisms in disease pathogenesis. His scholarly output includes first-author and single-author papers in leading journals, where he explores the roles of histone modifications, long noncoding RNAs, and nanobiosensor technologies in diagnostics and therapeutics. He has demonstrated academic leadership as an Editorial Board Member for Epigenomics and Molecular and Cellular Biochemistry and has served as a peer reviewer for over sixty high-impact journals. Recognized for his scientific excellence and editorial contributions, he has received the Best Researcher Award for his outstanding achievements in biomedical science. His ongoing work reflects a strong commitment to translational research, interdisciplinary collaboration, and mentorship of emerging scientists. With a clear vision for integrating molecular biology, nanotechnology, and clinical application, Dr. Shirvaliloo exemplifies the future of innovative medical research and continues to make significant contributions to global health advancement.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Heris, R. M., Shirvaliloo, M., Abbaspour-Aghdam, S., Hazrati, A., Shariati, A., & others. (2022). The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment. Stem Cell Research & Therapy, 13(1), 371.

2. Sheervalilou, R., Shirvaliloo, M., Dadashzadeh, N., Shirvalilou, S., Shahraki, O., & others. (2020). COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. Journal of Cellular Physiology, 235(12), 8873–8924.

3. Aghbash, P. S., Eslami, N., Shirvaliloo, M., & Baghi, H. B. (2021). Viral coinfections in COVID‐19. Journal of Medical Virology, 93(9), 5310–5322.

4. Shirvalilou, S., Khoei, S., Esfahani, A. J., Kamali, M., Shirvaliloo, M., & others. (2021). Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: A systematic review. Journal of Neuro-Oncology, 152(3), 419–428.

5. Razlansari, M., Jafarinejad, S., Rahdar, A., Shirvaliloo, M., Arshad, R., & others. (2023). Development and classification of RNA aptamers for therapeutic purposes: An updated review with emphasis on cancer. Molecular and Cellular Biochemistry, 478(7), 1573–1598.*

Dr. Milad Shirvaliloo’s pioneering research in epigenetics and nanomedicine bridges molecular science with clinical application, driving innovations in cancer and pulmonary disease diagnostics and therapies. His work advances precision medicine and fosters global scientific collaboration, contributing to more effective, personalized healthcare solutions.

Aneta Guzek | Bloodstream Infections | Best Researcher Award

Dr. Aneta Guzek | Bloodstream Infections | Best Researcher Award

Head of Microbial Laboratory | National Research Institute | Poland

Dr. Aneta Guzek is the Head of the Microbiology Laboratory at the Military Institute of Medicine – National Research Institute in Warsaw, Poland, specializing in medical microbiology and laboratory diagnostics. She holds a PhD in medicine with a specialization in medical microbiology from the Military Institute of Medicine, complemented by postgraduate qualifications in medical microbiology from the Medical University of Lublin and innovation management in the health care sector from Kozminski University. Additionally, she earned an MSc in biology with a focus on microbiology from the University of Warsaw and is a certified laboratory diagnostician. Dr. Guzek leads a multidisciplinary team overseeing comprehensive microbiological diagnostics, implementation of advanced diagnostic methods, and the development of institutional policies on infection control and antibiotic stewardship. Her research contributions include studies on antimicrobial resistance, hospital infection control, and the advancement of microbiological procedures, with numerous publications and citations in recognized scientific sources. She collaborates with national and reference laboratories, contributing to public health and medical innovation. Her exemplary service has been recognized with prestigious honors, including the first place in the Hippocrates Medical Poll for Laboratory Diagnostician of the Year and the Badge of Honour from the Military Medical Institute for her efforts during the COVID-19 pandemic. Dr. Guzek also holds certification in Good Clinical Practice (ICH E6 R2), underscoring her commitment to excellence in research and clinical integrity.

Profiles: Scopus | ORCID

Featured Publications

1. Guzek, A., et al. (2025). Microbiological comparison of maxillary sinus rinses in non-odontogenic and odontogenic sinusitis of primarily endodontic origin. Journal of Clinical Medicine.

2. Guzek, A., et al. (2024). Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in Poland. Journal of Clinical Medicine.

3. Guzek, A., et al. (2024). Dissemination of extensively drug-resistant NDM-producing Providencia stuartii in Europe linked to patients transferred from Ukraine, March 2022 to March 2023. Eurosurveillance.

Krzysztof Jeziorski | Oncology | Best Researcher Award

Dr. Krzysztof Jeziorski | Oncology | Best Researcher Award 

Department of Gerontology and Public Health at National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Dr. Krzysztof Grzegorz Jeziorski, MD, PhD, is a distinguished Polish oncologist with a career spanning over four decades in clinical and academic medicine. He has served as Associate Professor and Senior Assistant at the Maria Skłodowska-Curie National Research Cancer Institute in Warsaw since 1988 and continues to contribute as a Clinical Trials Consultant at the National Institute of Geriatrics, Rheumatology and Rehabilitation. Dr. Jeziorski’s professional path is marked by leadership in gastrointestinal cancer research, extensive clinical trial involvement, and international academic collaborations. A former Dean of the Faculty of Health Sciences and Social Sciences, he combines deep clinical expertise with academic excellence. He has participated in fellowships across Europe, including at the University of Oxford and the University of Padova. Renowned for his commitment to advancing cancer research, he continues to enhance his knowledge through postgraduate studies and remains actively engaged in both practice and education.

Professional Profile 

Scopus Profile
ORCID Profile 

Education

Dr. Jeziorski earned his medical degree from the Medical University of Warsaw, completing the I Medical Faculty. He later pursued advanced specialization, obtaining first and second-grade specialties in General Medicine and Chemotherapy of Cancer from the Medical Centre of Postgraduate Education. His passion for oncology led him to further achieve a specialty in Clinical Oncology and a Doctorate in Medical Sciences. In 2009, he was awarded the prestigious Habilitation degree from the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology. Dr. Jeziorski has continually enriched his education through prestigious fellowships and academic programs, including at the Universities of Oxford, Padova, Brussels, and Cambridge. He completed several key international training programs in epidemiology and public health. Recently, he completed postgraduate studies in Clinical Trial Methodology and is currently pursuing an MBA in Clinical Research and Biomedical Innovation Management at the Medical University of Warsaw, demonstrating his continued commitment to academic and professional growth.

Experience

Dr. Jeziorski brings a wealth of experience from clinical, academic, and administrative roles. Since 1988, he has been a leading figure at the Maria Skłodowska-Curie National Research Cancer Institute in Warsaw, serving as Associate Professor and senior assistant in the Outpatient Department for GI Cancers. He has also been a Clinical Trials Consultant at the National Institute of Geriatrics, Rheumatology and Rehabilitation since 2015. Earlier in his career, he worked with institutions like the Polish Academy of Sciences and served as Dean at the State Higher School of Pope John Paul II in Biała Podlaska. His clinical foundation was established at the Central Hospital of the Medical Academy in Warsaw. Dr. Jeziorski has managed over 20 international clinical trials as a Principal Investigator, contributing significantly to cancer research. His experience integrates scientific leadership, teaching, and hands-on patient care, making him a well-rounded and respected professional in medical oncology and research.

Awards and Honors

While a detailed list of awards is not provided in the curriculum vitae, Dr. Jeziorski’s academic journey includes several significant milestones that reflect a career of distinction. He received his Second Grade Specialty in Chemotherapy of Cancer with distinction, signaling outstanding academic and clinical performance. His international fellowships at elite institutions such as the University of Oxford, University of Padova, and University of Cambridge were awarded on a competitive basis and recognize his academic merit and research potential. Additionally, his long-term appointments at top-tier research institutes and his role as a Dean suggest institutional recognition of his expertise and leadership. Acceptance into high-profile postgraduate and international research training programs—including the Erasmus Summer Program and WHO/IDF seminars—further highlight his professional standing. His ongoing pursuit of an MBA in Clinical Research reflects both personal ambition and recognition of his evolving role in biomedical innovation and management.

Research Focus on Oncology

Dr. Jeziorski’s primary research focus lies in the field of gastrointestinal oncology, where he has made sustained contributions through clinical trials and academic leadership. He has acted as Principal Investigator in over 20 international clinical trials and participated in numerous additional studies as a Sub-Investigator. His research emphasizes improving therapeutic strategies for gastrointestinal neoplasms, with a strong interest in translating scientific findings into clinical practice. Dr. Jeziorski combines rigorous methodological training with deep clinical insight, as demonstrated by his postgraduate studies in clinical trial methodology and his continued education in research management. His international fellowships enriched his approach to evidence-based medicine and interdisciplinary collaboration. Throughout his career, he has actively worked to integrate public health perspectives and epidemiology into oncology research. By maintaining roles in both clinical care and research, Dr. Jeziorski ensures his work remains patient-centered, innovative, and aligned with global advances in cancer treatment.

Publications Top Notes

  • Title: Artificial Intelligence in Oncology

    • Authors: Krzysztof Jeziorski, Robert Olszewski

    • Year: 2024

  • Title: Lost in Communication: Do Family Physicians Provide Patients with Information on Preventing Diet-Related Diseases?

    • Authors: Robert Olszewski, Justyna Obiała, Karolina Obiała, Jakub Owoc, Małgorzata Mańczak, Klaudia Ćwiklińska, Magdalena Jabłońska, Paweł Zegarow, Jolanta Grygielska, Marzena Jaciubek, et al.

    • Year: 2022

  • Title: Hyperthermia in Rheumatic Diseases. A Promising Approach?

    • Author: Krzysztof Jeziorski

    • Year: 2018

  • Title: HER2 Status in GI Adenocarcinoma (TRIO-013/LOGiC Trial)

    • Authors: Press M.F., Ellis C.E., Gagnon R.C., Jeziorski K., et al.

    • Year: 2017

  • Title: Preservation of Duodenal Passage and Quality of Life After Gastrectomy

    • Authors: Olesiński T., Szpakowski M., Saramak P., Rutkowski A., Jeziorski K.

    • Year: 2017

  • Title: Rheumatic and Oncological Diseases – Common Challenges

    • Author: Krzysztof Jeziorski

    • Year: 2017

  • Title: Lapatinib + Chemotherapy in HER2+ GI Cancers (LOGiC Trial)

    • Authors: Hecht J.R., Bang Y.-J., Qin S.K., Jeziorski K., et al.

    • Year: 2016

  • Title: Preoperative Chemoradiation vs Short-Course Therapy in Rectal Cancer

    • Authors: Bujko K., Wyrwicz L., Rutkowski A., Jeziorski K., et al.

    • Year: 2016

  • Title: Validation of QLQ-GINET21 for GI Neuroendocrine Tumors

    • Authors: Yadegarfar G., Friend L., Jeziorski K., et al.

    • Year: 2013

  • Title: Efficacy of Y-90 DOTATATE in GEP-NETs – Phase II Study

    • Authors: Cwikla J.B., Sankowski A., Jeziorski K.G., et al.

    • Year: 2009

  • Title: Radiological Efficacy of 90Y-DOTATATE in Midgut NETs

    • Authors: Cwikla J.B., Sankowski A., Jeziorski K.G., et al.

    • Year: 2009

  • Title: Abscesses After Splenectomy in Gastric/Cardia Cancer Surgery

    • Authors: Szpakowski M., Olesiński T., Jeziorski K., et al.

    • Year: 2007

  • Title: Chemotherapy for Hepatocellular and Biliary Duct Cancers

    • Author: Krzysztof Jeziorski

    • Year: 2007

  • Title: Imaging of Gastroenteropancreatic NETs – Polish Center Experience

    • Authors: Cwikla J.B., Nasierowska-Guttmejer A., Jeziorski K.G., et al.

    • Year: 2007

  • Title: Leptomeningeal Metastases of EGJ Adenocarcinoma – Case Report

    • Authors: Olesiński T., Jeziorski K., Szawłowski A.

    • Year: 2007

Conclusion

Dr. Krzysztof Jeziorski exemplifies a distinguished researcher and clinician whose contributions to gastrointestinal oncology span over four decades. His involvement in high-impact, multi-center clinical trials, coupled with authorship in internationally recognized journals such as Journal of Clinical Oncology, Annals of Oncology, and British Journal of Cancer, highlights both the breadth and relevance of his work. He has consistently collaborated with global experts and participated in pivotal studies that influence cancer treatment protocols. His recent engagement with artificial intelligence in oncology indicates a forward-thinking and adaptive research approach. Although citation metrics for many of his publications are not readily available, the scope, continuity, and quality of his work speak to his lasting impact on cancer research. Dr. Jeziorski’s blend of clinical excellence, academic leadership, and international collaboration positions him as a highly deserving candidate for the Best Researcher Award, with a legacy that bridges science, innovation, and patient-centered care.

Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Dr. Laura Garriga-Grimau | Medicine and Dentistry | Best Researcher Award

Physician at Hospital Universitari Vall d’Hebron, Spain

Dr. Laura Garriga-Grimau is a dedicated pediatric pulmonologist based at Vall d’Hebron University Hospital in Barcelona, Spain. She specializes in bronchiectasis, cystic fibrosis, and other chronic pediatric lung conditions. Her work bridges clinical practice, academic research, and teaching. She is actively involved in multiple international research collaborations, including the European Respiratory Society (ERS) and the Child-BEAR-Net Registry. A strong advocate for improving respiratory care in children, Dr. Garriga-Grimau has authored numerous peer-reviewed publications and contributed to global studies shaping pediatric lung health guidelines. Her academic and clinical background is enriched by international clinical training in Australia and active teaching roles at the Autonomous University of Barcelona. Known for her collaborative leadership and deep scientific insight, she continues to contribute to innovation in pediatric respiratory medicine while mentoring future healthcare professionals. Her work is both evidence-driven and patient-centered, earning her a growing reputation in European and global pediatric research communities.

🔹 Professional Profile 

Scopus Profile
ORCID Profile 

🏆Strengths for the Award

Dr. Laura Garriga-Grimau has demonstrated a strong commitment to advancing pediatric respiratory medicine through a blend of clinical excellence, academic research, and international collaboration. Her specialization in bronchiectasis and cystic fibrosis has positioned her as a key contributor in areas that are often underrepresented in pediatric research. She currently holds leadership roles in prominent research initiatives, such as Chair of the ERS Task Force on Transitioning Adolescents with Bronchiectasis, and Deputy Co-Chair of the Child-BEAR-Net Registry, reflecting the recognition she commands within global respiratory research communities. These roles not only highlight her scientific insight but also her ability to coordinate multinational teams and influence clinical policy development.

Her publication record is both prolific and impactful, including research in The Lancet Respiratory Medicine, New England Journal of Medicine, and other peer-reviewed international journals. Dr. Garriga-Grimau has contributed to high-quality, multi-center studies and registries that address real-world challenges in diagnosis, treatment, and care models for pediatric lung diseases. Notably, her involvement in the SHIP-CT trial and the Spanish Pediatric Bronchiectasis Registry demonstrates her ability to participate in and lead complex clinical research initiatives with both academic and translational value. Her research outputs are data-driven, well-cited, and directly relevant to improving health outcomes in children globally.

In addition to her research achievements, Dr. Garriga-Grimau has actively bridged the gap between academia and clinical practice. She contributes as a faculty member in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona and has been involved in mentoring and training future clinicians and researchers. Her international clinical exposure, including a bronchiectasis fellowship in Australia, enhances the global relevance and cultural sensitivity of her work. This combination of academic productivity, clinical innovation, and leadership in international research networks makes her a well-rounded and highly deserving candidate for the Best Researcher Award.

🎓Education

Dr. Laura Garriga-Grimau completed her medical education and pediatric residency through the Spanish MIR system at the University of Barcelona, one of Spain’s leading academic medical centers. Following her pediatric training, she pursued specialized academic advancement through a Master’s degree in Pediatric Pulmonology from the Autonomous University of Barcelona (UAB), where she later became a faculty member. Her passion for research and respiratory medicine led her to complete a PhD focused on cystic fibrosis at Vall d’Hebron University Hospital, contributing significant findings to the field. In addition to her formal education, Dr. Garriga-Grimau enriched her academic and clinical knowledge with a training fellowship in bronchiectasis at the Queensland Children’s Hospital in Australia. Her continuous pursuit of learning, from clinical practice to translational research, has equipped her with a strong foundation in evidence-based medicine and multidisciplinary collaboration, shaping her into a leader in pediatric respiratory care both in Spain and internationally.

💼 Experience

Dr. Laura Garriga-Grimau has built an extensive and dynamic professional career in pediatric pulmonology, anchored at Vall d’Hebron University Hospital. She serves as a consultant in the Pediatric Pulmonology Department, where she treats complex respiratory conditions, including cystic fibrosis and bronchiectasis. Her clinical experience is complemented by her academic involvement as a lecturer in the Pediatric Pulmonology Master’s program at the Autonomous University of Barcelona. She completed international clinical training in Australia, focusing on bronchiectasis, and collaborates with research networks such as the ERS, ERN-Lung, and Child-BEAR-Net. Her career integrates hands-on patient care with data-driven research, highlighting her ability to translate science into practice. In leadership roles such as Chair of the ERS Task Force on adolescent bronchiectasis transition and Deputy Co-Chair of Child-BEAR-Net, she coordinates multinational teams and projects. Her balanced experience across clinical, research, and educational domains establishes her as a well-rounded and forward-thinking physician-scientist.

🏆 Awards and Honors

While specific individual awards are not listed in her profile, Dr. Laura Garriga-Grimau’s numerous prestigious roles and peer-reviewed publications serve as strong indicators of her academic and professional recognition. She has earned notable leadership positions in internationally recognized research bodies such as the European Respiratory Society (ERS) and the Child-BEAR-Net network, which are typically awarded based on merit, contribution, and peer endorsement. She is a key author and collaborator in top-tier journals including The Lancet Respiratory Medicine and The New England Journal of Medicine—an honor in itself that reflects a high level of expertise and scientific impact. Her inclusion in global studies and research registries, as well as her involvement in shaping clinical guidelines, affirms her reputation in the field of pediatric pulmonology. Furthermore, her appointment as faculty at a major academic institution and her PhD achievements represent high academic recognition within both national and international medical communities.

🔬Research Focus on Medicine and Dentistry

Dr. Garriga-Grimau’s research centers on pediatric bronchiectasis, cystic fibrosis, and related respiratory disorders, with an emphasis on improving diagnostics, treatment protocols, and health equity in chronic pediatric lung care. She is actively involved in several major international studies and registries, including the Child-BEAR-Net Registry and SHIP-CT trial. Her research evaluates multicountry clinical variations, healthcare transitions from adolescence to adulthood, and therapy optimization for children with chronic respiratory disease. She collaborates on translational studies that influence clinical guidelines and promote standardized care across different healthcare systems. Her work particularly emphasizes underserved populations, including Indigenous communities, reflecting her commitment to inclusive, global health research. By integrating clinical experience with robust epidemiological and translational approaches, Dr. Garriga-Grimau’s research not only advances scientific understanding but also directly enhances patient outcomes. She contributes to major publications and plays key roles in shaping pediatric pulmonology’s research priorities at the European and global level.

📚 Publications Top Notes

  • First results from the international paediatric bronchiectasis registry (Child‑BEAR‑Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cross‑sectional study

    • Authors: Laura Garriga‑Grimau; Ahmad Kantar; Keith Grimwood; Charl Verwey; Refiloe Masekela; Diane Gray; Ameena Goga; Bulent Karadag; Ela Erdem Eralp; Yasemin Gokdemir; et al.

    • Year: 2025

    • Citations: 1 (as per Scopus/ResearchGate)

  • Guiding practice principles for clinicians who work with Indigenous people

    • Authors: André Schultz; Anne B. Chang; Donna M. Mason; Julie M. Marchant; Lesley A. Versteegh; Maree Toombs; Laura Garriga‑Grimau; CRE Extended Group

    • Year: 2025

  • Bronchiectasis in pediatrics

    • Authors: Laura Garriga‑Grimau; Eva Polverino; Antonio Moreno‑Galdó

    • Year: 2025

  • Implementation of the Spanish Paediatric Bronchiectasis Registry (Child‑BEAR‑es Registry)

    • Authors: Laura Garriga‑Grimau; Verónica Sanz‑Santiago; Antonio Moreno‑Galdó

    • Year: 2024

  • Improving the Diagnosis and Treatment of Paediatric Bronchiectasis Through Research and Translation

    • Authors: Anne B. Chang; Shyamali C. Dharmage; Julie M. Marchant; Gabrielle B. McCallum; Peter S. Morris; Andre Schultz; Maree Toombs; Danielle F. Wurzel; Stephanie T. Yerkovich; Keith Grimwood; Laura Garriga‑Grimau; CRE extended group

    • Year: 2024

  • Asma (book chapter)

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • Pneumònia per Streptococcus pyogenes a l’edat pediàtrica

    • Author: Laura Garriga‑Grimau

    • Year: 2022

  • The effect of inhaled hypertonic saline on lung structure in children aged 3–6 years with cystic fibrosis (SHIP‑CT)

    • Authors: Harm A.W.M. Tiddens; Yuxin Chen; Eleni‑Rosalina Andrinopoulou; et al., including Laura Garriga‑Grimau

    • Year: 2022

  • Triple Therapy for Cystic Fibrosis Phe508del‑Gating and ‑Residual Function Genotypes

    • Authors: Peter J. Barry; Marcus A. Mall; Antonio Álvarez; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • How abnormal is the normal? Clinical characteristics of CF patients with normal FEV₁

    • Authors: Malena Cohen‑Cymberknoh; Elad Ben Meir; Silvia Gartner; et al., including Laura Garriga‑Grimau

    • Year: 2021

  • Earlier clinical case reports (2012–2015)

    • Authors: Laura Garriga‑Grimau et al.

    • Years: 2012–2015

📌 Conclusion

Dr. Laura Garriga-Grimau exemplifies the rare combination of clinical expertise, academic leadership, and collaborative spirit essential for advancing global pediatric pulmonology. Her commitment to research excellence, her leadership in multinational registries and task forces, and her drive to improve outcomes for children with chronic respiratory diseases mark her as an innovator in the field. Whether through her patient care, her mentorship of future specialists, or her groundbreaking studies in bronchiectasis and cystic fibrosis, Dr. Garriga-Grimau continues to push the boundaries of pediatric respiratory medicine. Her contributions resonate not only within academic journals but also in real-world clinical settings across borders. As she builds on her already distinguished career, she remains a key force in shaping the future of respiratory healthcare for children worldwide. Dr. Garriga-Grimau is undoubtedly a deserving candidate for any accolade recognizing research excellence, innovation, and global impact in medicine.

Yoana Dyankova | Medicine and Dentistry | Best Researcher Award

Dr. Yoana Dyankova | Medicine and Dentistry | Best Researcher Award

Doctor at Medical University, Varna, Bulgaria

Dr. Yoana Dyankova Dyankova is a dedicated pediatrician and clinical researcher specializing in pediatric gastroenterology, hepatology, and nutrition. She holds a PhD in Pediatrics from the Medical University “Prof. Dr. Paraskev Stoyanov” in Varna, Bulgaria, where she also serves in the Pediatric Intensive Care Unit at St. Marina University Hospital. Her research focuses primarily on celiac disease in children, particularly its impact on bone health, as demonstrated in her dissertation and multiple peer-reviewed publications, including a recent article in Nutrients (2025). Dr. Dyankova is an active member of national pediatric and gastroenterology associations and contributes to both clinical care and academic development. Fluent in English and German, she engages with the international scientific community and remains committed to translating research into improved patient outcomes. With her growing publication record, clinical integration, and academic rigor, she stands out as a promising young researcher in the field of pediatric medicine.

Professional Profile 

Google Scholar
ORCID Profile 

Education

Dr. Yoana Dyankova Dyankova began her academic journey at the Vasil Drumev High School of Natural Sciences and Mathematics in Veliko Tarnovo, graduating in 2010. She pursued her medical degree at the Medical University “Prof. Dr. Paraskev Stoyanov” in Varna, Bulgaria, completing it in 2016. From 2017 to 2022, she specialized in pediatrics, gaining comprehensive clinical training and board certification in the field. In 2018, she enrolled in a PhD program in Pediatrics at the same university, where she focused her research on celiac disease and its effects on pediatric bone health. She successfully defended her dissertation in 2023. Dr. Dyankova has since continued to develop professionally by pursuing further specialization in pediatric gastroenterology starting in July 2025. Her academic path demonstrates strong commitment, discipline, and a focused interest in improving pediatric healthcare through both clinical practice and rigorous scientific research.

Professional Experience

Dr. Dyankova has cultivated a balanced career combining clinical excellence and academic growth. Since January 2022, she has served as a pediatrician at the Pediatric Intensive Care Unit (PICU) of the First Children’s Clinic, St. Marina University Hospital in Varna. Her role in the PICU places her at the frontline of managing critically ill children, often requiring advanced decision-making and teamwork in high-pressure situations. Prior to this, she completed a five-year pediatric residency, gaining hands-on experience in general pediatrics. Her transition into the subspecialty of pediatric gastroenterology as of July 2025 marks a strategic shift aligned with her research interests. Parallel to her clinical duties, Dr. Dyankova was engaged in doctoral studies for five years, conducting original research and contributing to academic publications. Her dual role as both a clinician and researcher enhances her ability to apply scientific findings directly to patient care, making her a valuable asset in modern pediatric medicine.

Research Interest

Dr. Dyankova’s primary research interests lie at the intersection of pediatric gastroenterology, hepatology, and nutrition, with a concentrated focus on celiac disease (CD). Her doctoral thesis explored bone health in children with CD, addressing the metabolic and developmental complications arising from malabsorption and chronic inflammation. Beyond celiac disease, she has expressed research interest in related gastrointestinal disorders such as inflammatory bowel disease (IBD), as well as broader issues within pediatric intensive care. Her work is characterized by clinical relevance and translational value, aiming to bridge the gap between scientific research and bedside care. Publications in both national and international journals reflect her dedication to improving diagnostic and treatment protocols in children with chronic gastrointestinal conditions. Dr. Dyankova continues to build her research portfolio by participating in collaborative studies, focusing on early diagnosis, nutritional interventions, and long-term management outcomes in affected pediatric populations, ensuring a direct impact on clinical practice.

Award and Honor

While specific named awards are not listed in the biography, Dr. Yoana Dyankova Dyankova has received notable academic and professional recognition through her successful completion of a PhD and multiple scientific publications. Her research has been published in reputable journals such as Nutrients, indicating peer validation and relevance of her work. She is an active member of the National Pediatric Association and the community of Pediatric Gastroenterologists in Bulgaria, reflecting her standing in the professional community. These memberships signify not only recognition by peers but also her continued contribution to scientific discussions and advancements in pediatric healthcare. Her role in high-stakes clinical environments like the Pediatric Intensive Care Unit further demonstrates trust in her medical competence and decision-making. With growing academic output and clear specialization in a crucial field, Dr. Dyankova is well-positioned to earn future distinctions and leadership roles in pediatric research and clinical practice at both national and international levels.

Conclusion

Dr. Yoana Dyankova Dyankova exemplifies the qualities of a dedicated clinician-scientist, balancing hands-on pediatric care with high-impact academic research. With a solid foundation in pediatrics and a focused interest in gastroenterology and nutrition, she has steadily advanced her career through both clinical excellence and scholarly contribution. Her doctoral work on bone health in children with celiac disease highlights her ability to address complex, real-world health challenges through evidence-based research. Now working in a pediatric intensive care setting and continuing her subspecialty training, Dr. Dyankova is expanding her expertise and influence in critical areas of child health. Her publications, professional affiliations, and academic achievements underscore a deep commitment to the advancement of pediatric medicine. While still early in her career, her trajectory suggests strong potential for leadership in research and healthcare. She is a promising candidate for recognition such as the Best Researcher Award and is well-poised for continued professional impact.

Publications Top Notes

  1. Title: Presentation of Childhood Newly-Diagnosed Diabetes During the COVID-19 Pandemic – Is There a Change?

    • Authors: Y. Bazdarska, V. Iotova, T. Karamfilova, Y. Dyankova, T. Stefanova, …

    • Journal: Diabetes Technology & Therapeutics, Vol. 23, A202

    • Year: 2021

  1. Title: Delayed Bone Age and Osteoprotegerin Levels in Pediatric Celiac Disease: A Three-Year Case–Control Study

    • Authors: R. Pancheva, Y. Dyankova, N. Rasheva, K. Koleva, V. Iotova, M. Dzhogova, M. Fiore, M. Georgieva

    • Journal: Nutrients, Vol. 17 (14), Article 2295

    • Year: 2025

  1. Title: Macrophage Activation Syndrome After COVID-19 Infection in a Patient with Systemic Juvenile Idiopathic Arthritis

    • Authors: M. Boyadzhiev, B. Varbanova, M. Belcheva, P. Shivachev, D. Krumova, Y. Dyankova, …

    • Journal: Scripta Scientifica Medica, Vol. 55(1), pp. 27–31

    • Year: 2023

  1. Title: Bone Health in Children with Celiac Disease (PhD Dissertation)

    • Author: Y. Dyankova

    • Database: PQDT-Global (ProQuest Dissertations)

    • Year: 2022

  1. Title: New Developments in the Diagnostics of Celiac Disease in Children

    • Authors: Y. Dyankova, M. Georgieva, N. Rasheva, K. Koleva

    • Journal: Journal of the Union of Scientists-Varna. Medicine and Ecology Series, Vol. 24(1)

    • Year: 2019

  1. Title: Bacterial Pulmonary Colonization with Pseudomonas aeruginosa in Cystic Fibrosis Patients

    • Authors: M. Nikolova, Y. Dyankova, I. Hristov, M. Georgieva

    • Journal: Izvestia Journal of the Union of Scientists-Varna. Medicine and Ecology Series

    • Year: 2019

Dr. Javier Crespo | Medicine and Dentistry | Best Researcher Award

Dr. Javier Crespo | Medicine and Dentistry | Best Researcher Award

Professor at IDIVAL, Spain

Professor Javier Crespo is a distinguished physician-scientist and academic leader in the field of digestive and liver diseases. Currently a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL, he has made significant contributions through over 400 original publications, more than 120 clinical trials, and leadership in numerous national and international research projects. With an H-index of 70 and over 30,000 citations, his work has had a profound global impact. He has played a pivotal role in national health strategies, including Spain’s Hepatitis C elimination plan, and served as President of major professional societies such as SEPD. A mentor to numerous doctoral and master’s students, he has also received multiple prestigious awards for his contributions to medicine and research. His leadership at Marqués de Valdecilla University Hospital earned repeated national recognition for excellence in digestive and hepatitis care.

Professional Profile 

Google Scholar
Scopus Profile
ORCID Profile 

Education

Professor Javier Crespo earned his Degree in Medicine and General Surgery from the University of Cantabria with an Outstanding qualification. He later obtained his Doctorate in Medicine in 1993, receiving the Extraordinary Doctorate Award for academic excellence. His formal education laid a strong foundation for a career marked by clinical rigor and academic depth. In addition to his medical qualifications, he has been accredited as a Professor by ANECA (the Spanish National Agency for Quality Assessment and Accreditation). His academic journey reflects not only excellence in performance but also an enduring commitment to scientific learning and advancement. His scholarly trajectory is rooted in a lifelong dedication to the field of hepatology and digestive pathology, with an early focus on merging basic medical science with clinical research. These formative years have played a crucial role in shaping his influential career in medicine, teaching, and research.

Professional Experience

Professor Crespo has held several prestigious positions throughout his career. He is a Professor of Medicine at the University of Cantabria and Director of the Translational Research in Digestive Pathology group at IDIVAL. He served as Head of the Digestive Service at Marqués de Valdecilla University Hospital from 2010 to 2024. Additionally, he has played strategic roles in healthcare governance, including being a member of Spain’s National Strategic Plan against Hepatitis C since 2015 and coordinator of the AEEH National Liver Health Plan Challenge 2032. His leadership extends to professional societies—he served as President of the Spanish Society of Digestive Pathology (SEPD), President of the National Digestive Commission, and Secretary of the Spanish Association for the Study of the Liver. His professional career reflects a unique blend of clinical excellence, policy leadership, academic mentoring, and research management, making him one of the most respected figures in his specialty.

Research Interest

Professor Crespo’s primary research interests center around digestive and liver diseases, with a particular focus on hepatitis C, liver cirrhosis, and inflammatory bowel diseases. He has led more than 120 clinical trials across Phases I–III and participated in 15 national and 8 international competitive research projects. His translational approach bridges laboratory findings with clinical application, especially in hepatology. Under his leadership, the IDIVAL research group has produced high-impact findings in digestive pathology and liver disease progression. He has authored over 400 original scientific articles, with a strong presence in high-impact journals. His work is cited more than 30,000 times, and he holds an H-index of 70, underscoring his global influence. He is also actively involved in supervising doctoral and postgraduate theses, reflecting his dedication to advancing the next generation of researchers in gastroenterology. His research has contributed significantly to public health, particularly in the management and elimination of hepatitis C.

Award and Honor

Professor Javier Crespo has received numerous national and international awards that recognize both his scientific excellence and public health impact. Among his most prestigious accolades are the Elimination Champions 2023 International Award, granted by the Coalition for Global Hepatitis Elimination, and the International Award at the VI LIFE Forum for HCV Elimination in Lima (2024). Nationally, he has been honored with the Commendation of the Civil Order of Health, the SEPD Gold Medal, and the ACAD Gold Medal. He was also named an Illustrious Torrelaveguense in 2024. Under his leadership, the Digestive Service at Marqués de Valdecilla University Hospital received the Best in Class Award for several consecutive years for excellence in digestive and hepatitis care. His honors reflect not only scientific merit but also his dedication to clinical service and public health leadership, making him one of the most decorated professionals in his field.

Conclusion

In conclusion, Professor Javier Crespo is a highly accomplished and impactful leader in the fields of gastroenterology and hepatology. His career combines outstanding academic achievement, clinical leadership, and translational research excellence. With more than 30,000 citations and an H-index of 70, his scientific contributions have shaped current practices in liver disease treatment and public health strategies. He has held top-level positions in hospitals, universities, research institutes, and national health commissions, evidencing his multifaceted influence. Through his mentorship, he has cultivated a generation of researchers and clinicians, further extending his legacy. His work has not only garnered national and international recognition through prestigious awards but has also led to meaningful improvements in patient care, especially in hepatitis C management. Professor Crespo exemplifies the qualities of a visionary researcher, a compassionate physician, and a dedicated educator—making him exceptionally worthy of recognition such as the Best Researcher Award.

Publications Top Notes

  • Carvedilol vs. propranolol for the prevention of decompensation and mortality in patients with compensated and decompensated cirrhosis

    • Authors: Not listed

    • Year: 2025

    • Citations: 3

  • Letter to the Editor: Optimizing MASLD treatment—A “lead-in phase” before resmetirom

    • Authors: Not listed

    • Year: Not listed

    • Citations: 1

  • Comprehensive Diagnosis of Viral Hepatitis in Spain: Bases for Implementation

    • Authors: Not listed

    • Year: 2025

  • Unraveling MASLD: The Role of Gut Microbiota, Dietary Modulation, and AI-Driven Lifestyle Interventions

    • Authors: Not listed

    • Year: Not listed

    • Citations: 1

  • A multisociety Delphi consensus statement on new fatty liver disease nomenclature

    • Authors: ME Rinella, JV Lazarus, V Ratziu, SM Francque, AJ Sanyal, F Kanwal, …

    • Year: 2023

    • Citations: 4,096

  • Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn’s disease

    • Authors: N Inohara, Y Ogura, A Fontalba, O Gutierrez, F Pons, J Crespo, K Fukase, …

    • Year: 2003

    • Citations: 2,245

  • Modeling NAFLD disease burden in 8 countries (2016–2030)

    • Authors: C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, …

    • Year: 2018

    • Citations: 2,027

  • A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

    • Authors: HSA Newsome, PN Buchholtz, K Cusi, M Linder, T Okanoue, V Ratziu, S Sanyal, …

    • Year: 2021

    • Citations: 1,673

  • Obeticholic acid for the treatment of NASH: Phase 3 trial analysis

    • Authors: ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, …

    • Year: 2019

    • Citations: 1,286

  • Elafibranor resolves NASH without fibrosis worsening

    • Authors: SA Ratziu, V Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, …

    • Year: 2016

    • Citations: 1,217

  • Sofosbuvir and ribavirin in HCV genotypes 2 and 3

    • Authors: ER Zeuzem, S Dusheiko, GM Salupere, R Mangia, A Flisiak, RH Hyland, …

    • Year: 2014

    • Citations: 1,048

  • A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis

    • Authors: Not listed

    • Year: 2024

    • Citations: 983

  • Gene expression of TNF-α and TNF receptors in NASH patients

    • Authors: J Crespo, A Cayón, P Fernández‐Gil, M Hernández‐Guerra, M Mayorga, …

    • Year: 2001

    • Citations: 971

  • Advancing the global public health agenda for NAFLD: Consensus statement

    • Authors: JV Lazarus, HE Mark, QM Anstee, JP Arab, RL Batterham, L Castera, …

    • Year: 2022

    • Citations: 683

Daniel Akyeampong | Medicine and Dentistry | Best Researcher Award

Dr. Daniel Akyeampong | Medicine and Dentistry | Best Researcher Award

General Surgery Resident at Medical University of South Carolina, United States

Dr. Daniel K. Akyeampong, MD, born on August 13, 1993, is an emerging leader in the field of general surgery and medical education. Currently a resident in General Surgery at the Medical University of South Carolina, he has demonstrated a profound commitment to both clinical practice and academic achievement. He holds dual roles as a mentor and educator, fostering future physicians while simultaneously contributing to advancements in surgical care. A natural communicator, Daniel excels in patient-centered care and effective communication, which has earned him multiple recognitions, including the Trauma Llama Award in 2025. His dedication to the medical field is complemented by his active involvement in various professional societies such as the American College of Surgeons and the Eastern Association for the Surgery of Trauma. With a focus on both clinical excellence and research, Daniel is poised to make significant contributions to the medical community in the years to come.

Education

Daniel K. Akyeampong’s educational journey reflects a deep commitment to academic excellence and medical innovation. He earned his Bachelor of Science degree from Virginia Commonwealth University in 2015, graduating cum laude. Following his undergraduate studies, Daniel pursued his Doctor of Medicine (MD) at the University of Virginia School of Medicine, completing his degree in 2021. His rigorous academic training was followed by an internship at Vanderbilt University in General Surgery, before he embarked on his residency at the Medical University of South Carolina. Throughout his education, Daniel consistently demonstrated a passion for both learning and teaching, as evidenced by his involvement in multiple teaching and mentorship roles. His academic achievements are further underscored by prestigious awards, including the Bowman Scholar award and numerous merit scholarships, which highlight his academic dedication and promise as a future leader in the medical field.

Professional Experience

Daniel K. Akyeampong has accumulated valuable professional experience in both clinical practice and academic settings. His clinical journey began during his internship in General Surgery at Vanderbilt University, where he honed his surgical skills and deepened his understanding of patient care. In 2022, Daniel began his residency at the Medical University of South Carolina, continuing to develop his expertise in general surgery. He has actively participated in various trauma and surgical care initiatives, where his communication and patient-centered approach have earned him recognition. Additionally, Daniel’s leadership abilities extend beyond patient care, as he has taken on roles such as Administrative Chief Resident for 2025. His involvement in various committees, including the James Ramsay Surgical History Society and the Medical Society of Virginia, highlights his commitment to advancing the profession through service and leadership. Daniel’s experience as a Nationally Certified Pharmacy Technician also adds to his comprehensive understanding of healthcare systems, further enhancing his capability as a surgeon and educator.

Research Interests

Dr. Daniel Akyeampong’s research interests primarily focus on the intersection of surgery, trauma care, and medical education. He has a keen interest in exploring clinical and surgical innovations that enhance patient outcomes, particularly in trauma and emergency surgical settings. Daniel’s research has already been acknowledged with a Larry S. Nichter Research Award finalist recognition, which highlights his potential for making significant contributions to the field. He is particularly driven by the need for advancements in surgical techniques and protocols that improve patient survival rates in trauma situations. In addition to his clinical research interests, Daniel is dedicated to the advancement of medical education, focusing on improving teaching methods and mentorship in surgical training. His interest in education is evident in his multiple awards for teaching excellence and his active involvement in mentoring medical students and residents. By combining clinical expertise with research, Daniel seeks to contribute to both practical improvements in patient care and the academic growth of future surgeons.

Awards and Honors

Throughout his medical career, Dr. Daniel Akyeampong has received numerous awards and honors that reflect his dedication, excellence, and leadership within the medical community. Notable among these is the Trauma Llama Award (2025), recognizing his exceptional communication and patient-centered care during pediatric trauma activations. Additionally, Daniel has earned the Resident Award for Excellence in Student Teaching (2023, 2024), which highlights his outstanding contributions to medical education and his role in mentoring medical students. He has also been nominated for the prestigious Golden Apple Excellence in Teaching Award in 2023 and 2024, an honor given to faculty members nominated by students for excellence in teaching. As a finalist for the Larry S. Nichter Research Award in 2021, Daniel has demonstrated his commitment to impactful research in the medical field. His academic excellence is further underscored by several merit-based scholarships, such as the Bowman Scholar award and the Society of the Cincinnati Scholarship. These awards serve as a testament to his potential for continued success in both academic and clinical medicine.

Conclusion

Daniel K. Akyeampong shows strong potential for the Best Researcher Award, particularly through his combination of academic excellence, clinical expertise, and leadership. His research contributions, while recognized, could be enhanced by a more robust publication record and broader scope of research. With more focus on these areas, he has the potential to become a leading figure in surgical and clinical research.

Publications Top Notes

  • Epidemiology of Symptomatic Non-Union/Malunion Rib Fractures

    • Author: Daniel Akyeampong, Alexander Hoey, Ronald Gross, Evert Eriksson

    • Year: 2025

    • Citation: Akyeampong D, Hoey A, Gross R, Eriksson E. Epidemiology of Symptomatic Non-Union/Malunion Rib Fractures. Surgeries. 2025 Apr; 6(2):32. DOI: 10.3390/surgeries6020032

  • Anatomy of the Interchondral Joints and the Effects on Mobility of Ribs

    • Author: Daniel Akyeampong, Alexander Hoey, Aakash Patel, Andrew Privette, William Ganske, Justin Halmark, Christopher Muir, Steven Kubalak, Evert Eriksson

    • Year: 2024

    • Citation: Akyeampong D, Hoey A, Patel A, Privette AR, Ganske W, Halmark J, Muir C, Kubalak SW, Eriksson EA. Anatomy of the Interchondral Joints and the Effects on Mobility of Ribs. The Journal of Trauma and Acute Care Surgery. 2024 Sep 6; DOI: 10.1097/ta.0000000000004430

  • Racial and Gender Discrimination in Hand Surgery Letters of Recommendation

    • Author: Bradford PS, Daniel Akyeampong, MA 2nd Fleming, Andrew Dacus, AB Chhabra, DEGEORGE BRENT

    • Year: 2021

    • Citation: Bradford PS, Akyeampong D, Fleming MA 2nd, Dacus AR, Chhabra AB, DeGeorge B. Racial and Gender Discrimination in Hand Surgery Letters of Recommendation. The Journal of Hand Surgery. 2021 Aug 20; DOI: 10.1016/j.jhsa.2021.07.009

  • Three-dimensional Printing and Craniosynostosis Surgery

    • Author: Soldozy S, K. Yağmurlu, Daniel K. Akyeampong, Richard Burke, PF Morgenstern, RF Keating, JS Black, JA Jane Jr, HR Syed

    • Year: 2021

    • Citation: Soldozy S, Yağmurlu K, Akyeampong DK, Burke R, Morgenstern PF, Keating RF, Black JS, Jane JA Jr, Syed HR. Three-dimensional Printing and Craniosynostosis Surgery. Child’s Nervous System. 2021 Mar 29; DOI: 10.1007/s00381-021-05133-8

  • Systematic Review of Functional Mapping and Cortical Reorganization in the Setting of Arteriovenous Malformations, Redefining Anatomical Eloquence

    • Author: Soldozy S, Daniel K. Akyeampong, DL Barquin, Pedro Norat, Kaan Yağmurlu, JD Sokolowski, KA Sharifi, P Tvrdik, MS Park, MYS Kalani

    • Year: 2020

    • Citation: Soldozy S, Akyeampong DK, Barquin DL, Norat P, Yagmurlu K, Sokolowski JD, Sharifi KA, Tvrdik P, Park MS, Kalani MYS. Systematic Review of Functional Mapping and Cortical Reorganization in the Setting of Arteriovenous Malformations, Redefining Anatomical Eloquence. Frontiers in Surgery. 2020 Sep 30; DOI: 10.3389/fsurg.2020.514247

  • Consequences of Chronic Frequent Premature Atrial Contractions: Association with Cardiac Arrhythmias and Cardiac Structural Changes

    • Author: Sampath Gunda, Daniel Akyeampong, J. Gomez-Arroyo, Daniel G. Jovin, Gurukripa Narayan Kowlgi, Karoly Kaszala, Tan AY, JN Koneru, Jordana Kron, KA Ellenbogen et al.

    • Year: 2019

    • Citation: Gunda S, Akyeampong D, Gomez-Arroyo J, Jovin DG, Kowlgi GN, Kaszala K, Tan AY, Koneru JN, Kron J, Ellenbogen KA. Consequences of Chronic Frequent Premature Atrial Contractions: Association with Cardiac Arrhythmias and Cardiac Structural Changes. Journal of Cardiovascular Electrophysiology. 2019 Aug 1; DOI: 10.1111/jce.14067